Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CDW Holding ( (SG:BXE) ) is now available.
CDW Holding Limited announced that its subsidiary, ABio, has signed a joint research and development agreement with Neoregen Biotech Co., Ltd. for the advancement of next-generation Lipid Nanoparticle (LNP) technology. This collaboration will allow ABio to deepen its research capabilities in LNP technology and mRNA vaccines, creating synergies through shared proprietary know-how and technology between the two companies.
More about CDW Holding
CDW Holding Limited is engaged in antibody research and drug development through its subsidiary, ABio. The company focuses on creating recombinant antibodies using its proprietary library, and is expanding into lipid nanoparticle technology as part of its market focus.
YTD Price Performance: -7.07%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.44M
See more data about BXE stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts